Advertisement

Advertisement

ASCO Plenary Series

Skin Cancer
Immunotherapy
Genomics/Genetics

DREAMseq Trial: In Advanced Melanoma With BRAF Mutations, Start With Immunotherapy

Caroline Helwick  /  December 10, 2021

 In the treatment of patients with advanced melanoma containing BRAF mutations, initial treatment with an immunotherapy combination achieved superior overall survival compared with targeted therapy in the phase III DREAMseq trial, also known as the ECOG-ACRIN EA6134 trial. The results were reported ...

Advertisement

Advertisement



Advertisement